Auch hier wäre ein Link auf die Studie hilfreich. Ein kurze Suche ergibt:

N-acetylcysteine for the treatment of COVID-19 among hospitalized patients
https://www.journalofinfection.com/article/S0163-4453(21)00329-7/fulltext

Highlights

Low serum levels of H2S in COVID-19 pneumonia are associated with a poor prognosis.
Endogenous H2S production can be increased therapeutically by administering NAC.
NAC therapy was associated with improvement in SpO2/FiO2, CRP, and NEWS2 scale.
There were no significant differences in the clinical outcomes (IMV, mortality).
NAC therapy was not associated with moderate and severe adverse events.

N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study
https://pubmed.ncbi.nlm.nih.gov/34182881/

Results:
A total of 82 patients were included, 42 in the NAC group and 40 in the control group. Treatment with oral NAC led to significantly lower rates of progression to SRF as compared to the control group (p < .01). Patients in the NAC group presented significantly lower 14- and 28-day mortality as compared to controls (p < .001 and p < .01 respectively). NAC treatment significantly reduced 14- and 28-day mortality in patients with severe disease (p < .001, respectively). NAC improved over time the PO2/FiO2 ratio and decreased the white blood cell, CRP, D-dimers and LDH levels. In the multivariable logistic regression analysis, non-severe illness and NAC administration were independent predictors of 28-days survival.

A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome
https://link.springer.com/article/10.1007/s43440-021-00296-2

Results

No differences were found in the 28-day mortality rate between the two groups (25.5% vs. 31.1% in the NAC and placebo groups, respectively). Although the distribution of the clinical status at day 28 shifted towards better outcomes in the NAC-treated group, it did not reach a statistical significance level (p value = 0.83). Similar results were achieved in terms of the proportion of patients who required invasive ventilator support (38.3% vs. 44.4%), the number of ventilator-free days (17.4 vs. 16.6), and median time of ICU and hospital stay. Results regarding the change in PaO2/FiO2 ratio and SOFA scores also showed no significant differences between the groups.

Leider ein gemischtes Bild.

Meine Erfahrung seit langem ist, daß NAC bei verschleimten Bronchien bei mir überhaupt nicht hilft. Mucosolvan geht aber super. Eine damalige schnelle Suche im Internet ergab, daß NAC dort, wo der Schleim sitzt, in den Luftkanälen, kaum hinkommt, und deshalb nicht wirken kann. Ein typischer Fall dafür, daß etwas nur in Vitro funktioniert.

All die anderen Punkte bzgl. NAC treffen natürlich zu. Besonders wichtig ist die Funktion bei der Reduktion der ROS. NAC ist Gegenmittel bei Paracetamolvergiftung, und hilft der Leber beim Alkoholabbau (Anti-Kater-Mittel) - auch hier Stichwort ROS.

Wer genaueres über die Mechanismen erfahren will, dem empfehle ich die Videos von MedCRAM vom letzten Jahr.

Coronavirus Pandemic Update 65: COVID-19 and Oxidative Stress (Prevention & Risk Factors)
https://www.youtube.com/watch?v=gzx8LH4Fjic

Coronavirus Pandemic Update 69: "NAC" Supplementation and COVID-19 (N-Acetylcysteine)
https://www.youtube.com/watch?v=Dr_6w-WPr0w

Coronavirus Pandemic Update 70: Glutathione Deficiency, Oxidative Stress, and COVID 19
https://www.youtube.com/watch?v=OtL0B1bqXak

Wenn ich mich erinnere, dann waren das die wichtigsten Videos dazu.

Grüße

--


Afuera!